Premium
Identification of Predictive Proteins and Biological Pathways for the Tumorigenicity of Vestibular Schwannoma by Proteomic Profiling
Author(s) -
Xu Jianhui,
Zhang Yang,
Shi Yuxuan,
Yin Dongming,
Dai Peidong,
Zhao Weidong,
Zhang Tianyu
Publication year - 2019
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201800175
Subject(s) - carcinogenesis , kegg , biology , downregulation and upregulation , blot , immunohistochemistry , cancer research , gene ontology , computational biology , gene , bioinformatics , gene expression , microbiology and biotechnology , pathology , genetics , medicine , immunology
Purpose Vestibular schwannomas (VSs) are benign tumors that account for 8–10% of all intracranial tumors. So far, the tumorigenesis of VS has not been fully elucidated. This study is designed to identify differently expressed proteins involved in VS tumorigenesis. Experimental Design An isobaric tag is used for relative and absolute quantification (iTRAQ) approach to characterize the protein expression profiles from pooled VS tissues ( n = 12) and pooled matched normal vestibular tissues ( n = 12). Results A total of 933 differentially expressed proteins are identified between VS and the matched normal vestibular tissues, with 489 being upregulated and 444 being downregulated. Bioinformatics analyses are performed according to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. Several of the differentially expressed proteins are validated by western blotting analyses, and upregulation of LGALS1, ANXA1, GRB2, and STAT1 is validated in VS tissue by immunohistochemistry. Conclusions and Clinical Relevance The study represents the successful application of iTRAQ technology to an investigation of VS. Many of the differentially expressed proteins identified here have not been linked to VS before, and these dysregulated proteins may provide potential biomarkers for human VS diagnosis.